BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 36694244)

  • 1. Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma.
    Mistry V; Scott JR; Wang TY; Mollee P; Miles KA; Law WP; Hapgood G
    Cancer Imaging; 2023 Jan; 23(1):11. PubMed ID: 36694244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas.
    Maccioni F; Alfieri G; Assanto GM; Mattone M; Gentiloni Silveri G; Viola F; De Maio A; Frantellizzi V; Di Rocco A; De Vincentis G; Pulsoni A; Martelli M; Catalano C
    Radiol Med; 2023 May; 128(5):556-564. PubMed ID: 37145214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Verhagen MV; Menezes LJ; Neriman D; Watson TA; Punwani S; Taylor SA; Shankar A; Daw S; Humphries PD
    J Nucl Med; 2021 Nov; 62(11):1524-1530. PubMed ID: 33608429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard.
    Littooij AS; Kwee TC; Barber I; Granata C; Vermoolen MA; Enríquez G; Zsíros J; Soh SY; de Keizer B; Beek FJ; Hobbelink MG; Bierings MB; Stoker J; Nievelstein RA
    Eur Radiol; 2014 May; 24(5):1153-65. PubMed ID: 24563179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including
    Latifoltojar A; Punwani S; Lopes A; Humphries PD; Klusmann M; Menezes LJ; Daw S; Shankar A; Neriman D; Fitzke H; Clifton-Hadley L; Smith P; Taylor SA
    Eur Radiol; 2019 Jan; 29(1):202-212. PubMed ID: 29948084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
    Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
    van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
    AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D; Patti C; Lagalla R; Midiri M; Galia M
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body MRI versus an [
    Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; de Keizer B; Nievelstein RAJ
    Eur Radiol; 2021 Dec; 31(12):8925-8936. PubMed ID: 34021390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
    Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
    Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study.
    Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Elias SG; van de Brug T; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; Greer MC; de Keizer B; Nievelstein RAJ
    Eur Radiol; 2021 Mar; 31(3):1494-1504. PubMed ID: 32880696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of FDG PET/MR and PET/CT for staging, response assessment, and prognostic imaging biomarkers in lymphoma.
    Husby T; Johansen H; Bogsrud T; Hustad KV; Evensen BV; Boellard R; Giskeødegård GF; Fagerli UM; Eikenes L
    Ann Hematol; 2022 May; 101(5):1077-1088. PubMed ID: 35174405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studies.
    Regacini R; Puchnick A; Shigueoka DC; Iared W; Lederman HM
    Sao Paulo Med J; 2015; 133(2):141-50. PubMed ID: 25789779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET/MR versus PET/CT for locoregional staging of oropharyngeal squamous cell cancer.
    Flygare L; Erdogan ST; Söderkvist K
    Acta Radiol; 2023 May; 64(5):1865-1872. PubMed ID: 36464816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
    Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H
    J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between glycolytic activity on [18F]-FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging.
    Giraudo C; Karanikas G; Weber M; Raderer M; Jaeger U; Simonitsch-Klupp I; Mayerhoefer ME
    J Magn Reson Imaging; 2018 May; 47(5):1217-1226. PubMed ID: 29086453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Sequential PET/MRI in Comparison With PET/CT of Pediatric Lymphoma: A Prospective Study.
    Sher AC; Seghers V; Paldino MJ; Dodge C; Krishnamurthy R; Krishnamurthy R; Rohren EM
    AJR Am J Roentgenol; 2016 Mar; 206(3):623-31. PubMed ID: 26901021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of diffusion-weighted MRI and [
    Morakote W; Baratto L; Ramasamy SK; Adams LC; Liang T; Sarrami AH; Daldrup-Link HE
    Eur Radiol; 2024 Jan; 34(1):643-653. PubMed ID: 37542653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.